Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Laureate, Tolerx Enter Manufacturing Pact | Contract Pharma

What are you searching for?

Sign in
Breaking News

Laureate, Tolerx Enter Manufacturing Pact

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Laureate Pharma has entered into a cGMP contract manufacturing agreement with Tolerx, Inc. to produce Tolerx’s humanized anti-GITR antibody known as TRX518, which is currently in development for cancer and chronic viral indications. Details of the agreement were not disclosed.
   
“The partnership with Tolerx validates the progress we have made in biomanufacturing and our commitment in helping our clients bring novel therapies to the market,” said Robert J. Broeze, Ph.D., president and chief executive officer of Laureate. “With our well-established monoclonal antibody experience, we will partner closely with the Tolerx team to help them achieve their manufacturing objectives.”
   
“Laureate Pharma has a proven track record in biopharmaceutical manufacturing, including capabilities in both clinical and commercial-grade materials,” said Dr. Douglas J. Ringler, president and chief executive officer of Tolerx. “This agreement enables us to operationally leverage Laureate’s expertise and infrastructure while we seek to establish new treatment paradigms in the immunology space.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters